SAN DIEGO, June 13 (Bernama-GLOBE NEWSWIRE) — Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, today announced four new preclinical translational NASH models in development.
NASH is a degenerative liver disease that affects up to 12 percent of the adult population worldwide and without treatment is expected to become the leading cause for liver transplant by 2020. Today there are no approved drugs to treat NASH.